Thorac Cardiovasc Surg 2006; 54(3): 188-192
DOI: 10.1055/s-2005-872953
Original Thoracic

© Georg Thieme Verlag KG Stuttgart · New York

Effect and Duration of Lung Volume Reduction Surgery: Mid-Term Results of the Brompton Trial

E. Lim1 , A. Ali1 , N. Cartwright1 , I. Sousa2 , A. Chetwynd2 , M. Polkey3 , D. Geddes3 , J. Pepper1 , P. Diggle2 , P. Goldstraw1
  • 1Department of Thoracic Surgery, Royal Brompton Hospital, London, United Kingdom
  • 2Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom
  • 3Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom
Further Information

Publication History

Received August 7, 2005

Publication Date:
26 April 2006 (online)

Abstract

Although many studies have reported improvement in lung function following LVRS, the magnitude of improvement and subsequent decline has not been evaluated against medical therapy after the second year. Methods: Existing pulmonary function records were collated for each participant since randomisation from the Brompton LVRS trial cohort. Longitudinal data analysis was used to profile the history of medically treated patients and the effect of LVRS. Results: Pulmonary function results were collated from survivors over a median of 25 (17 to 39) months. The estimated immediate increase in mean FEV1 following surgery was + 0.259 l (0.179, 0.339), with a rate of change of - 0.005 l (- 0.009, - 0.001) per month compared to medical therapy (p < 0.001). The changes in the secondary outcome measures (LVRS compared to medical therapy) were an increase in FVC (p = 0.004), decrease in RV (p < 0.001) and TLC (p < 0.001), with differences that were maintained over time. The initial reduction in RV/TLC ratio was sustained (p < 0.001), but the estimated initial increase in peak flow was accompanied by a gradual decline that was not statistically significant (p = 0.062). KCOc showed no immediate change, but there was a gradual sustained increase with time (p = 0.009). Mean oxygen saturations improved and continued to do so compared to patients on medical therapy (p = 0.001). Conclusion: The immediate increase in FEV1 is not sustained, although the mechanical improvements of LVRS on increasing FVC, reducing both the RV and RV/TLC ratio, appear to be maintained. The important benefits of LVRS may be the gradual and sustained increase in transfer factor accompanied by improved oxygen saturations.

References

  • 1 Criner G J, Cordova F C, Furukawa S, Kuzma A M, Travaline J M, Leyenson V, O'Brien G M. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1999;  160 2018-2027
  • 2 Geddes D M. Lung volume reduction surgery.  Thorax. 1999;  54 (Suppl 2) S14-18
  • 3 National Emphysema Treatment Trial Research Group . A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema.  N Engl J Med. 2003;  348 2059-2073
  • 4 Bloch K E, Georgescu C L, Russi E W, Weder W. Gain and subsequent loss of lung function after lung volume reduction surgery in cases of severe emphysema with different morphologic patterns.  J Thorac Cardiovasc Surg. 2002;  123 845-854
  • 5 Ciccone A, Meyers B, Guthrie T, Davis G, Yusen R, Lefrak S, Patterson G, Cooper J. Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema.  J Thorac Cardiovasc Surg. 2003;  125 513-525
  • 6 Gelb A F, McKenna J RJ, Brenner M, Epstein J D, Zamel N. Lung function 5 yr after lung volume reduction surgery for emphysema.  Am J Respir Crit Care Med. 2001;  163 1562-1566
  • 7 Diggle P J, Heagerty P, Liang K Y, Zeger S L. Analysis of Longitudinal Data. 2nd edn. Oxford; University Press 2002
  • 8 Cox D R. Regression models and life tables (with discussion).  J R Statist Soc B. 1972;  34 187-220
  • 9 Geddes D, Davies M, Koyama H, Hansell D, Pastorino U, Pepper J, Agent P, Cullinan P, MacNeill S J, Goldstraw P. Effect of lung-volume-reduction surgery in patients with severe emphysema.  N Engl J Med. 2000;  343 239-245
  • 10 Berger R L, Celli B R, Meneghetti A L, Bagley P H, Wright C D, Ingenito E P, Gray A, Snider G L. Limitations of randomized clinical trials for evaluating emerging operations: the case of lung volume reduction surgery.  Ann Thorac Surg. 2001;  72 649-657
  • 11 The National Emphysema Treatment Trial Research Group . Rationale and design of The National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery.  Chest. 1999;  116 1750-1761
  • 12 National Emphysema Treatment Trial Research Group . Patients at high risk of death after lung-volume-reduction surgery.  N Engl J Med. 2001;  345 1075-1083
  • 13 Blackstone E. Breaking down barriers: Helpful breakthrough statistical methods you need to understand better.  J Thorac Cardiovasc Surg. 2001;  122 430-439
  • 14 Matthews J N, Altman D G, Campbell M J, Royston P. Analysis of serial measurements in medical research.  BMJ. 1990;  300 230-235
  • 15 Fessler H E, Scharf S M, Permutt S. Improvement in spirometry following lung volume reduction surgery: application of a physiologic model.  Am J Respir Crit Care Med. 2002;  165 34-40
  • 16 Sciurba F C, Rogers R M, Keenan R J, Slivka W A, Gorcsan R J, Ferson P F, Holbert J M, Brown M L, Landreneau R J. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema.  N Engl J Med. 1996;  334 1095-1099
  • 17 Rogers R M. Stress-relaxation in pulmonary emphysema and its relation to airway conductance.  Am Rev Respir Dis. 1970;  101 452-453
  • 18 Little R JA, Rubin D B. Statistical Analysis with Missing Data. New York; Wiley 1987

Professor Peter Goldstraw

Department of Thoracic Surgery, Royal Brompton Hospital

Sydney Street

London SW3 6NP

United Kingdom

Phone: + 442073528121

Fax: + 44 20 73 51 84 73

Email: p.goldstraw@rbh.nthames.nhs.uk

    >